| | ||||||||||
| 1 | INN | Class | Route (list) | PK parameters= Cmax; Tmax; F: bioavailability; t1/2: half-life; VD: volume of distribution; Cl: clearance; PPB: plasma protein binding;(EQN means that value was calculated using VD=(Cl*t1/2)/0.693) | Primary Target and PDB code of Protein-Drug complex | Targets from DrugCentral | Links | |||
| VANDETANIB
| VANDETANIB | ANTINEOPLASTIC | ORAL | Cmax 1.7 MICROMOLAR (300 MILLIGRAM) VD 7450 LITER PPB 90 PERCENT Cl 13.2 LITER / HOUR (300 MILLIGRAM) HT 456 HOUR SOLUBILITY IS PRACTICALLY INSOLUBLE IN WATER WITH A VALUE OF 0.008 MILLIGRAM / MILLILITER AT 25 DEGRE CELSIUS | EGFR VEGF PROTEIN TYROSINE KINASE 6 (BRK) TIE2 EPH RECEPTORS KINASE FAMILY SRC FAMILY PDB 2IVU (CRYSTAL STRUCTURE OF PHOSPHORYLATED RET TYROSINE KINASE DOMAIN COMPLEXED WITH THE INHIBITOR ZD6474) LIGAND CODE = ZD6 (link to the list of PDB complexes) Download experimental 3D coordinates of ZD6 with added hydrogens | Epidermal growth factor receptor UNIPROT P00533 EGFR -- Proto-oncogene tyrosine-protein kinase receptor Ret UNIPROT P07949 RET more at DrugCentral | EMA | |||
